BioCentury
ARTICLE | Clinical News

ArteFill: Phase III data

May 20, 2013 7:00 AM UTC

A double-blind, U.S. Phase III trial in about 177 patients with moderate to severe atrophic acne scars showed that ArteFill met the primary endpoint of a greater response rate, defined as a 2-point im...